Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Complement-mediated Disorders”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Testing effectiveness (Phase 2)Ended earlyNCT03459443
What this trial is testing

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Alexion Pharmaceuticals, Inc. 22
Testing effectiveness (Phase 2)Looking for participantsNCT07522099
What this trial is testing

Chinese Adults With Kidney Disease

Who this might be right for
Immunoglobulin A Nephropathy (IgAN)Complement 3 Glomerulopathy (C3G)IC-MPGN
ADARx Pharmaceuticals, Inc. 30
Testing effectiveness (Phase 2)Study completedNCT03369236
What this trial is testing

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Who this might be right for
C3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease
Alexion Pharmaceuticals, Inc. 13
Early research (Phase 1)Study completedNCT03316521
What this trial is testing

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Who this might be right for
Complement Mediated Diseases
Amyndas Pharmaceuticals S.A. 50
Not applicableEnded earlyNCT05095623
What this trial is testing

A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease

Who this might be right for
Recurrent Bacterial Infection, Autoimmune Disorder
Catalyst Biosciences 3
Not applicableAvailableNCT04288713
What this trial is testing

Eculizumab (Soliris) in Covid-19 Infected Patients

Who this might be right for
Coronavirus
Hudson Medical
Testing effectiveness (Phase 2)Looking for participantsNCT06989359
What this trial is testing

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Who this might be right for
IgANC3GComplement-mediated Kidney Disease+2 more
ADARx Pharmaceuticals, Inc. 45
Post-approval studies (Phase 4)Study completedNCT07290855
What this trial is testing

Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema

Who this might be right for
Bradykinin-mediated AngioedemaHereditary Angioedema (HAE)
Nang Kuang Pharmaceutical Co., Ltd. 5
Early research (Phase 1)UnknownNCT06560593
What this trial is testing

Clinical Trial of NTQ5082 in Healthy Volunteers

Who this might be right for
Complement-mediated Hemolytic Diseases
Nanjing Chia-tai Tianqing Pharmaceutical 82
Not applicableWithdrawnNCT05304091
What this trial is testing

Characterization of Rhythmicity Profiles of Bradykinin-mediated Angioedema Attacks Using a Tracking Smartphone Application.

Who this might be right for
Bradykinin-mediated Angioedema
University Hospital, Lille
Large-scale testing (Phase 3)Study completedNCT02013037
What this trial is testing

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

Who this might be right for
Antibody-mediated RejectionHyperacute Rejection of Cardiac TransplantLeft Ventricular Dysfunction+2 more
Cedars-Sinai Medical Center 36
Testing effectiveness (Phase 2)Study completedNCT05083364
What this trial is testing

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Who this might be right for
C3 GlomerulopathyIgA Nephropathy
Arrowhead Pharmaceuticals 62
Testing effectiveness (Phase 2)Looking for participantsNCT07046806
What this trial is testing

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Who this might be right for
Hereditary Angioedema (HAE)AngioedemaBradykinin-mediated Angioedema+1 more
Institute for Asthma and Allergy 10
Early research (Phase 1)UnknownNCT06558656
What this trial is testing

Effect of Food of NTQ5082 in Healthy Subjects

Who this might be right for
Complement-mediated Hemolytic Diseases
Nanjing Chia-tai Tianqing Pharmaceutical 12
Not applicableNot Yet RecruitingNCT07331259
What this trial is testing

CHART-C3G/CLNP023B12011

Who this might be right for
C3 GlomerulopathyComplement-mediated Kidney DiseaseProteinuria
Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Active Not RecruitingNCT06786338
What this trial is testing

SGB-9768 in Patients With Complement-mediated Kidney Diseases

Who this might be right for
IgA Nephropathy (IgAN)C3 GlomerulopathyIC-MPGN
Suzhou Sanegene Bio Inc. 45
Early research (Phase 1)Study completedNCT06567392
What this trial is testing

Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers

Who this might be right for
Complement Mediated Primary or Secondary Glomerular Diseases
Chengdu Suncadia Medicine Co., Ltd. 6
Early research (Phase 1)Study completedNCT06674915
What this trial is testing

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

Who this might be right for
Complement Mediated Primary or Secondary Glomerular Diseases
Chengdu Suncadia Medicine Co., Ltd. 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05517980
What this trial is testing

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Who this might be right for
Glomerulonephritis
Kira Pharmacenticals (US), LLC. 52
Testing effectiveness (Phase 2)Looking for participantsNCT06853223
What this trial is testing

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Who this might be right for
Primary Graft DysfunctionLung TransplantationAcute Lung Injury(ALI)+1 more
University of California, San Francisco 120
Next Page